Effect of agomelatine on cerebral activity measured by functional magnetic resonance imaging (MRI) in patients with major depressive disorder in comparison to healthy volunteers

Submission date	Recruitment status No longer recruiting	Prospectively registered		
30/10/2008		∐ Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
26/11/2008		[X] Results		
Last Edited 20/04/2020	Condition category Mental and Behavioural Disorders	[] Individual participant data		

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)

Scientific

Contact name

Prof Philippe Fossati

Contact details

CHU Pitié-Salpêtrière - 47 Bd de LHôpital Paris France 75013

Additional identifiers

Clinical Trials Information System (CTIS) 2007-005564-27

Protocol serial number

CL2-20098-067

Study information

Scientific Title

Effect of agomelatine on cerebral activity measured by functional magnetic resonance imaging (MRI) in patients with major depressive disorder in comparison to healthy volunteers

Study objectives

To assess the effect of agomelatine compared to placebo, on cerebral activation measured by functional magnetic resonance imaging (fMRI) in major depressive disorder patients. Comparison to functional MRI profiles of healthy volunteers.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received on the 09/07/2008 by CPP Ile de France VI

Study design

Randomised double-blind placebo-controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Major depressive disorder

Interventions

Agomelatine 25 mg versus placebo.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Agomelatine

Primary outcome(s)

Functional magnetic resonance imaging.

Key secondary outcome(s))

- 1. Functional magnetic resonance imaging
- 2. Hamilton Rating Scale for Depression (HAM-D), Time point: baseline to week 24
- 3. Clinical Global Impression (CGI), Time point: baseline to week 24
- 4. Sleep (Leeds Sleep Evaluation Questionnaire [LSEQ]), Time point: baseline to week 24
- 5. Safety, Time point: baseline to week 24

Completion date

Eligibility

Key inclusion criteria

Amended 02/12/2010:

1. Healthy volunteers and patients: between 25 and 53 years, female

initial information at time of registration

- 1. Healthy volunteers and patients: between 25 and 50 years, female
- 2. Out-patients fulfilling Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for major depressive disorder (MDD)

Participant type(s)

Mixed

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Total final enrolment

44

Key exclusion criteria

- 1. Women of childbearing potential without effective contraception
- 2. Patients meeting DSM-IV-TR current diagnosis of psychiatric disorder other than MDD

Date of first enrolment

29/09/2008

Date of final enrolment

29/02/2012

Locations

Countries of recruitment

France

Study participating centre CHU Pitié-Salpêtrière - 47

Paris

France

75013

Sponsor information

Organisation

Institut de Recherches Internationales Servier (France)

ROR

https://ror.org/034e7c066

Funder(s)

Funder type

Industry

Funder Name

Institut de Recherches Internationales Servier (France)

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com if a Marketing Authorisation has been granted after 1st January 2014.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No
Basic results			20/04/2020	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes